---
title: DaVita (DVA) — intrinsic value and fair price
canonical: https://sweetvaluelab.com/stocks/dva
ticker: DVA
as_of: 2026-10-17
sector: Healthcare
industry: Medical - Care Facilities
---
# DaVita (DVA)

DaVita (DVA) closed at $187.31 on Oct 16, 2026, undervalued by 65% vs its model value of $528.85 (from a five-year discounted cash flow).

## Key figures

| Figure | Value |
| --- | ---: |
| Last close | $187.31 (Oct 16, 2026) |
| Model value (from a five-year discounted cash flow) | $528.85 |
| Price vs model | undervalued by 65% vs model |
| Range of that model | $236.82 – $1,392.24 |
| Market value | $12.0B |
| P/E (fiscal 2025) | 19.0 |
| Net margin (fiscal 2025) | 5.5% |
| Free cash flow (fiscal 2025) | $1.3B |
| Dividend yield (trailing twelve months) | 0.00% |
| Beta | 0.80 |
| Cost of capital (WACC) | 6.56% |
| Business classification | Mature & Stable (Low/slowing growth (~6% recent), Moderate margins (5% net margin), Highly cyclical earnings, High leverage (D/E 5.0x), Strong FCF yield (11.0%)) |

## On the stock lists

| List | Place | Figure | Page |
| --- | ---: | ---: | --- |
| Highest free cash flow yield | #23 | 11.0% | https://sweetvaluelab.com/lists/highest-free-cash-flow-yield |
| Best performing this year | #26 | +64.9% | https://sweetvaluelab.com/lists/best-performing-this-year |

## Valuation models

Each model's value per share and the role the engine gave it for this business. The headline above is one model's value; every other model is listed with its own, and each has a page of its own under the valuation. Computed Oct 17, 2026.

| Model | Role | Value per share | Low | High |
| --- | --- | ---: | ---: | ---: |
| DCF · Perpetuity growth · 5y | primary | $528.85 | $236.82 | $1,392.24 |
| DCF · Perpetuity growth · 10y | cross check | $538.86 | $255.35 | $1,412.65 |
| DCF · EBITDA exit · 5y | cross check | $601.88 | $412.54 | $824.77 |
| DCF · EBITDA exit · 10y | cross check | $599.14 | $390.81 | $876.36 |
| P/E · peers | cross check | $118.76 | $118.76 | $118.76 |
| P/E · own history | cross check | $182.53 | $154.88 | $222.69 |
| PEG | sanity check | $370.63 | $370.63 | $370.63 |
| EV/EBITDA · peers | cross check | $757.42 | $537.60 | $977.23 |
| EV/Revenue · peers | cross check | $91.40 | $76.27 | $201.05 |
| Earnings power value | cross check | $175.12 | $118.98 | $264.55 |
| Dividend discount | cross check | $0.00 | $0.00 | $0.00 |

## Insider activity (SEC Form 4)

Past 90 days: 0 open-market buys ($0) and 1 open-market sale ($36.5M); 10b5-1 plan sales included.

| Date | Insider | Relationship | Transaction | Shares | Value |
| --- | --- | --- | --- | ---: | ---: |
| Sep 22, 2026 | Maughan David Paul | Chief Operating Officer, DKC | Tax withholding | 7,501 | $1.4M |
| Aug 15, 2026 | Hollar Jason M. | Director | Grant / award | 278 | $0 |
| Aug 15, 2026 | DESOER BARBARA J | Director | Grant / award | 278 | $0 |
| Aug 15, 2026 | Schechter Adam H | Director | Grant / award | 278 | $0 |
| Aug 15, 2026 | Moore Gregory J. | Director | Grant / award | 278 | $0 |

## Recent SEC filings

| Filed | Form | What | Filing |
| --- | --- | --- | --- |
| Aug 4, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/927066/000092706626000108/dva-20260630.htm |
| Aug 4, 2026 | 8-K | 2.02 Results of Operations (Earnings); 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/927066/000092706626000105/dva-20260804.htm |
| Jun 8, 2026 | 8-K | 1.01 Entry into a Material Agreement; 2.03 Creation of a Direct Financial Obligation; 5.07 Submission of Matters to a Shareholder Vote; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/927066/000120677426000316/dva4647631-8k.htm |
| May 5, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/927066/000092706626000062/dva-20260331.htm |
| May 5, 2026 | 8-K | 2.02 Results of Operations (Earnings); 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/927066/000092706626000060/dva-20260505.htm |

## Superinvestors holding it (latest 13F)

| Manager | Quarter | Shares | Value |
| --- | --- | ---: | ---: |
| Buffett | 2026-06-30 | 28,880,209 | $6.4B |
| Bridgewater | 2026-06-30 | 10,996 | $2.4M |

2 tracked managers in all.

## About

DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrat…

---

Source: https://sweetvaluelab.com/stocks/dva (SweetValueLab, free, no account). Prices and statements from Financial Modeling Prep; filings from SEC EDGAR. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.